You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to September 2024

AbstractFullPdf
Nov 2023560044
Dec 2023205012
Jan 2024188024
Feb 2024118014
Mar 202414405
Apr 2024136011
May 2024138010
Jun 202412908
Jul 2024206018
Aug 2024264025
Sep 2024153015
Total22410186